Once-Weekly Semaglutide in Adolescents with Obesity.

Studied

A randomized placebo-controlled trial tested weekly semaglutide plus lifestyle intervention in adolescents with obesity or qualifying overweight.

Who / model

Adolescents with obesity, or overweight plus a weight-related condition, were eligible.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Semaglutide reduced BMI more than placebo and improved several cardiometabolic risk factors. Gastrointestinal adverse events were more common with semaglutide.

Limits

Gastrointestinal adverse events were more frequent with semaglutide, and cholelithiasis occurred only in that group.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary